FDA grants accelerated approval to sevabertinib for non-squamous NSCLC
FDA grants accelerated approval to sevabertinib for locally advanced/metastatic non-squamous NSCLC, per statement.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.